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Background
Tumour growth rate is a prognostic marker and can be evaluated by its correlate at the 
cellular level: mitoses. Thus, mitotic counts are used in a wide number of neoplasms to 
predict prognosis, and highly proliferative neoplasms (with many mitoses) usually have 
a worse prognosis. Mitotic counts are performed by a pathologist, counting mitotic fig-
ures at a high magnification. As mitotic figures are rare in relation to the number of cells, 
10 high power fields (HPF) of view are typically examined. As cellularity is time consum-
ing to quantify, mitoses/area is often used instead of mitoses/cell.
Considered as a sampling problem, mitotic counting is, typically biased in a number 
of ways: (1) many pathologists do not start the count until they have found one mitosis, 
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(2) pathologists count mitoses in the area of the tumour they consider to be the most 
mitotically active (usually the most poorly differentiated portion). The former introduces 
a systematic bias that consistently skews the results in the direction towards a higher 
mitotic score. The later factor is not a significant factor if one frames the problem as an 
assessment of the poorly differentiated region of the tumour (as opposed to the tumour 
as a whole).
In breast pathology, mitotic counts are a part of the Nottingham score and have 
been demonstrated to be a histomorphologic predictor of outcome. The procedure for 
counting mitoses was laid-out in the original paper that described the scoring system 
[1], and has subsequently been clarified in the CAP protocol, where it states it should 
be done on the “most mitotically active area”. The system recognizes that mitotic rate 
per area is a strong predictor and essentially standardizes the cut-points (3 and 8 
mitoses/mm2) to two separate mitotic rates (mitoses/area), creating a three tier sys-
tem. The system pseudo-standardizes the sample area to 10 HPF, where one HPF is 
the field area seen with the 40x objective and dependent on the field diameter of the 
microscope.
Mitotic counting in breast pathology has been considered a sampling problem and 
it has been studied experimentally and modelled mathematically [3]. Experimentally 
assessing the reproducibility of mitotic counts rigorously is an onerous proposition, and 
it would be prohibitively expensive to do a large study from which the misclassification 
errors due to sampling can be accurately assessed. The reproducibility of mitotic counts 
in the context of breast pathology is “low” [3]; thus, small sample sizes (< 50 cases) are 
not sufficient. Unselected breast cancer cases are usually mitotic score 1, and this makes 
a study of misclassification more onerous, as the effect size is smaller than it would be if 
the cases are equally distributed among the different scores.
A computer simulation of this problem is an elegant solution as it can avoid the oner-
ous labour and control for many confounders. Populations of simulated specimens can 
be randomly sampled, and compared to the true mitotic rates. Such a gold standard 
comparison is not possible using glass slides and pathologists. This can be done millions 
of times to determine the distribution of correct and incorrectly classified simulated 
specimens, and is a powerful tool for demonstrating the effect of sampling 10 HPFs from 
microscopes with different field areas.
The area of a HPF measured in mm2 may vary considerably from microscope to 
microscope. Using the smallest and largest field diameters from the table in the College 
of American Pathologists (CAP) checklist for Invasive Breast Cancer [2], a microscope 
with a field diameter of 0.40  mm has a HPF area of 0.13  mm2, while one with a field 
diameter of 0.69 mm has a HPF area of 0.37 mm2. This is almost a three-fold difference 
in the area sampled in one HPF.
HPF is a tenuous pseudo-standard and, unfortunately, this measure is widely used 
throughout pathology, from eosinophilic esophagitis [4] to gastrointestinal stromal 
tumours [5], and breast cancer [6] to mention a few. It has been recognized that the HPF, 
an often used measure of area, has no uniform definition and is a significant and under 
recognized source of variability that can lead to misclassification affecting reproducibil-
ity. As a result, there has been a gradual move toward establishing standardized sample 
Page 3 of 8Bonert and Tate  BioMed Eng OnLine  (2017) 16:28 
areas, e.g. 5 mm2 for gastrointestinal stromal tumour [5]; however, it stubbornly persists 
in many areas of pathology.
Sampling problems, similar to mitotic counting, are all around us, and differences in 
sample size significantly effect predictions. A public opinion survey with 1000 individu-
als is more representative of the population than one with 500 individuals. This paper 
will show the same applies for the sample area, and will demonstrate how large the effect 
of sample size is in the context of breast cancer mitotic scoring.
This paper will rigorously assess the impact of the sample area on the mitotic score in 
the three-tier system used in breast pathology and it will demonstrate that a standard-
ized sample area is essential.
Methods
An in silico model was developed based on the binomial distribution [7], using the 
software GNU Octave (www.gnu.org/software/octave/). The model assumes mitotic 
counting is a sampling problem. It assessed the classification and misclassification 
rates of 1,000,000 simulated breast specimens, using the sample areas for the extremes 
of the field diameter range (FD =  0.40  mm, 10 HPF =  1.26  mm2, FD =  0.69  mm, 10 
HPF = 3.74 mm2) in the College of American Pathologists (CAP) checklist [6], as well as 
the areas of 5.00 mm2, which would be equivalent to 40 HPF at a FD 0.40 mm, or almost 
14HPF for FD 0.69 mm.
Each simulated breast specimen was assigned a true mitotic density, based on an 
experimentally determined distribution from Meyers et al. The mitotic rate in the popu-
lation ranged from 0 to 16.4 mitoses/mm2 and is similar to the distribution seen in an 
unselected population; however, has more cases in the higher mitotic score categories.
Then, in essence, the cumulative probability of each simulated mitotic count was cal-
culated based on the knowledge of (1) the true mitotic rate per area, (2) the sample area, 
and (3) the cellular density. One such (sampled) mitotic count-probability distribution is 
seen in Fig. 1. The abscissa of Fig. 1 shows the (sampled) mitotic count (abscissa) versus 
the cumulative probability (ordinate).
The sampling processes, i.e. the simulated mitotic counts, were each represented by 
a random number between 0 and 1, which were considered equivalent to the percentile 
score of all possible sampling results. Thus, the random numbers could be substituted 
for the cumulative probability—in the (sampled) mitotic count–probability distributions 
(i.e. Fig.  1)—and thus converted to the sampled mitotic counts. The sampled mitotic 
counts were subsequently converted into (sampled) mitotic scores. The true and sam-
pled mitotic scores were then determined based on the true and sampled mitotic densi-
ties, using the cutoffs of 3 and 8 mitoses/mm2 as in 2013 version of the CAP checklist 
[2], and the misclassification or agreement was tabulated. For each of the 1,000,000 cases 
the cellular density (2500 cells/mm2) was held constant.
For example:
If the random generated number is 0.42644 the mitotic score is determined to be 7, as 
the random number is less than the cumulative probability for 7 mitoses (0.45285) and 
greater than the cumulative probably for 6 mitoses (0.31318).
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The number of specimens with a particular mitotic rate for the sample population are 
shown in Fig.  1, which was interpolated to generate a table of mitotic rates and their 
relative frequency in the population of specimens.
Results
The percentage of agreement between the true mitotic rate and the sampled mitotic 
rate based on the three different sampled areas, 1.24, 3.74, and 5.00 mm2, are given in 
Tables 1, 2, and 3 respectively, for 1,000,000 simulated breast specimens. Some rounding 
and significant digits lead to totals not adding up to 100%. Additionally the accuracy, for 
each HPF area was also calculated. The misclassification rates are 16, 9, 8, 5, 4 and 4% for 
sample areas of 1.26, 3.74, 5, 10, 15 and 20 mm2 respectively (see Table 4). If one frames 
the comparison between the true mitotic score and the score generated by the simulated 
of mitotic count, as an inter-rater reliability problem, Cohen’s kappa is applicable as a 
measure. The kappa is 0.76, 0.87, 0.89, 0.92, 0.93 and 0.94 for sample areas of 1.26, 3.74, 
5, 10, 15 and 20 mm2 respectively.
Fig. 1 Cumulative probability (based on the binomial distribution) versus the mitotic count for a set of 
parameters (sample area = 2 mm2, cells/area = 2500 cells/mm2, true mitotic rate = 4.0 mitoses/mm2)









Sample score 1 96 37 <1 72
Sample score 2 4 55 25 18
Sample score 3 <1 8 75 9









Sample score 1 95 14 0 68
Sample score 2 5 82 18 22
Sample score 3 0 4 82 10
Page 5 of 8Bonert and Tate  BioMed Eng OnLine  (2017) 16:28 
Discussion
The three-tier system reproducibly separates score 1 and score 3; the lowest sample area 
(1.26 mm2) has less than 1% of cases misclassified as score 1 when it is truly score 3.
Intuitively, the middle group should have a higher misclassification rate than the 
other two, as it directly interfaces with the two other groups. The model reproduces this 
expected pattern; the middle group has the highest misclassification rate.
The smallest field diameter microscopes (0.40 mm), due to sampling error, incorrectly 
categorize an additional of 7% of all tumors when compared to the largest field diameter 
microscopes (0.69 mm), 27% more of cases in the mitotic score 2 group.
The results reproduce findings by Meyer et  al.; the misclassification rate is quite 
high (9–16% of cases). There is a clear trend to less misclassification with greater sam-
ple areas and the misclassification rate has a non-linear relationship with the sample 
area where incremental increases in area have successively lower reductions in the 
misclassification rate, as shown by the flattening of the misclassification from 5 to 
20 mm2 (Table 4).
The accuracy strong depends on the true mitotic rate, as a plot of the fraction incor-
rect versus the true mitotic rate demonstrates, Fig. 2.
Limitations
The study did not consider the common practise of beginning the mitotic count with a 
mitotic figure. The effect of this practise could be calculated; however, it adds another 
level of complexity and likely does not change the overall conclusions. As well, the study 
did not systematically assess the impact of cellularity in the simulated breast specimens; 
however, some smaller calculations suggest it is not a significant factor (data not shown).
The findings are not corroborated by a large data set with patient outcomes and sam-
ple areas. This is a true short coming; however, we are not in possession of such a data 
set, though we hope this study will spurn some data mining by others. These findings 









Sample score 1 96 12 0 68
Sample score 2 4 83 13 22
Sample score 3 0 5 87 1
Table 4 Accuracy by area of all classifications of simulated breast specimens
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regarding sampling theory as it applies to simulated breast specimens are practically 
self-evident, particularly if examined in the context of the vast experience with similar 
problems in opinion research (public polling) and manufacturing (statistical process 
control).
Conclusions
Ten HPF is not a good standard sample area, as the misclassification rate is dependent 
on the microscope. The reproducibility of the mitotic score is poor, especially when close 
to the CAP Protocol cut-points of 3 and 8 mitoses/mm2 (see Fig.  2; Additional file  1: 
Appendix S1).
The mitotic count cut-points should be standardized and the sample area standard-
ized; this could be accomplished by varying the number of HPFs counted and may be 
less complicated than the table in the CAP checklist (see Additional file 2: Appendix S2).
Reducing misclassification
Generally, reducing the misclassification error requires a larger sample area, as noted 
by Meyer et al. [3]. However, we believe advocating larger sample areas (>5 mm2) would 
be impractical and needlessly tedious, as many cases can be assessed with a relatively 
small area. Also, as we have shown, a number of cases close to the cut-point, considered 
practically, will frequently be misclassified unless one samples the whole or at least the 
entirety of the most poorly differentiated component, of the tumour.
We believe a more rational approach would be to triage cases into (a) “needs a larger 
sample area”, and (b) “confident it is correctly classified”. The triage decision would 
be guided by a count on a (small) standardized sample area and a confidence interval 
around the cut-points. Cases deemed to need a larger sample area would be classified 
based on the larger sample area. We believe it is reasonable to draw the line after limited 
additional sampling; with a statement about the confidence interval—to make the clini-
cian aware that a number of the cases will be misclassified by chance so that it can be 
Fig. 2 Missclassification versus true mitotic rate
Page 7 of 8Bonert and Tate  BioMed Eng OnLine  (2017) 16:28 
taken into account. It is possible that some pathologists might already do such an activ-
ity, by performing repeated counts in several areas (Additional file 3).
We strongly believe that the term “high power field” and its cousins (“intermediate 
power field”, and “low power field”) should be completely abandoned as measures of area 
in pathology. Their continued use is offensive to any person that has given thought to 
why measures (such as the foot, millimeter and kilogram) are standardized or has some 
understanding of sampling theory.
Accurately quantifying proliferation will likely remain important for predicting can-
cer outcomes in the near term. Proliferative activity is used to subclassify breast cancer, 
has been quantified with Ki-67 labeling, and is central to commercial ancillary tests for 
breast cancer, e.g. Oncotype Dx [8].
The issue identified in this paper may explain, in part, why alternatives to the mitotic 
count have been sought; mitotic counts done by humans have limitations and have been 
done without much attention to sampling theory.
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Appendix
The following in an outline of the calculation. Words in quotes refer to the variable 
names in the program:
1. The expected number of mitoses (“m_expected”) is calcualted from the (randomly 
generated) true mitotic rate (“true_mitotic_rate”), using the sample area (“sample_
area”).
2. The (binomial distribution) cumulative probability (“cdf_at_m_expected”) is calcu-
lated (using GNU Octave “binocdf” function) from the expected number of mitoses 
(“m_expected”), sample area (“sample_area”) and true mitotic rate divided by the 
cells per area (“TP”).
3. The number of mitoses counted (“m”) is then solved for by incrementally adding 
or subtracting from “m_expected” until the random sampling value (“P_sample”) is 
bounded by the (binomial distribution) cumulative probability of “m” and “m + 1” or 
“m” and “m-1”.
4. The mitotic count cut-points (“m_cp1” and “m_cp2”) are calculated from the mitotic 
rate cut-points (“cp1” and “cp2”) by, multiplying the mitotic rate cut-points by the 
sample area and rounding to the nearest mitosis.
5. The sampled mitotic count (“m”) is compared to the cut-points (“m_cp1” and “m_
cp2”) to determine the sample mitotic score (“sample_m_score”).
6. The expected number of mitoses (“m_expected”) is compared to the cut-points (“m_
cp1” and “m_cp2”) to determine the (true) mitotic score.
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